Trial reportJournal of the American Academy of Dermatology2021
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
Trial report in Journal of the American Academy of Dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 11 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Efficacy and Safety of Oral Janus Kinase Inhibitors in Adults and Adolescents with Alopecia Areata: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.American journal of clinical dermatology · 2026Pooled it
- Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis.Archives of dermatological research · 2024Pooled it
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.JAMA network open · 2023Pooled it
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.Clinical drug investigation · 2023Pooled it
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis.Acta dermato-venereologica · 2023Pooled it
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients.Frontiers in immunology · 2023Pooled it
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.Frontiers in immunology · 2023Pooled it
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies.Frontiers in pharmacology · 2022Pooled it
- The effect of combined pudendal nerve and spermatic cord block or caudal epidural block on postoperative analgesia after posterior urethroplasty: a randomized trial.BMC anesthesiology · 2024Trial
- How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach.Dermatology and therapy · 2026Article
- Article
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020-2023.Dermatology and therapy · 2025Review
- Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians.Skin appendage disorders · 2025Review
- Efficacy and Safety of Long-Term Azathioprine Therapy for Severe Alopecia Areata: A 10-Year Cohort Study.Journal of cosmetic dermatology · 2025Article
- Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study.Cureus · 2025Article
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies.MedComm · 2025Review
- Statistical Inference for a Two-Stage Adaptive Seamless Design Using Different Binary Endpoints.Statistics in medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are no treatments approved by the Food and Drug Administration for alopecia areata.
objectiveTo evaluate the efficacy and safety of baricitinib in patients with ≥50% scalp hair loss in a phase 2 study of adults with alopecia areata (BRAVE-AA1).
methodsPatients were randomized 1:1:1:1 to receive placebo or baricitinib 1 mg, 2 mg, or 4 mg once daily. Two consecutive interim analyses were performed after all patients completed weeks 12 and 36 or had discontinued treatment prior to these time points. The primary endpoint was the proportion of patients achieving a Severity of Alopecia Tool (SALT) score ≤20 at week 36. Logistic regression was used with nonresponder imputation for missing data.
resultsA total of 110 patients were randomized (placebo, 28; baricitinib 1-mg, 28; 2-mg, 27; 4-mg, 27). The baricitinib 1-mg dose was dropped after the first interim analysis based on lower SALT LIMITATIONS: Small sample size limits generalizability of results.
conclusionThese results support the efficacy and safety of baricitinib in patients with ≥50% scalp hair loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.